As of October 22, 2026, BioNTech SE (BNTX) trades at $89.00. No model fair value is published for BNTX. BNTX reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — BNTX valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
BioNTech SE (BNTX) is next scheduled to report earnings on Nov 3, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $0.85.
Reported EPS came in above the analyst estimate in 3 of the last 8 reports. The median share-price change across a report, in either direction, was 2.8%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Aug 4, 2026 | $-2.58 | $-3.03 | -17.4% | -1.0% |
| May 5, 2026 | $-1.92 | $-1.95 | -1.6% | -3.9% |
| Mar 10, 2026 | $-0.25 | $-0.33 | -33.5% | -17.9% |
| Nov 3, 2025 | $0.10 | $-0.12 | -220.0% | +0.0% |
| Aug 4, 2025 | $-1.41 | $-1.60 | -13.5% | +2.5% |
| May 5, 2025 | $-2.35 | $-1.73 | +26.4% | -3.7% |
| Mar 10, 2025 | $0.48 | $1.08 | +126.6% | -3.1% |
| Nov 4, 2024 | $-1.61 | $0.81 | +150.3% | -2.3% |
Equity Rank's fundamental strength composite scores BNTX at 49.2/100 (C, Adequate), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at -72.7% per year and gross margin has moved -5.1 pp. Its SAVE composite score has moved -0.4 over the past 30 days.
BNTX reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
BioNTech SE (BNTX) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
BioNTech SE (BNTX) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Biotechnology stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/BNTX. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.